The Cambridge Life Sciences team advised Tay on entering into a license agreement with VYNE Therapeutics, under which VYNE obtained exclusive rights to Tay’s oral BET inhibitor, TAY-B2 (VYN202).
This is the second licence between Tay and VYNE that the Goodwin team have advised on. In 2021, Goodwin advised Tay on out-licencing its topical pan-BET inhibitor to VYNE for £16 million in upfront and milestone payments. The out-licensing of both of Tay Therapeutics’ BET inhibitor projects will now bring potential milestone revenues of over $65 million for the first indications along. In addition, it will yield royalty payments of up to 10% of net annual sales.
The Goodwin team was led by Tim Worden and Georgia Powell.
For additional details on the agreement, please see coverage in the PharmaTimes.